Mantle cell lymphoma activation enhances bortezomib sensitivity

Area of Science:

• Oncology
• Immunology
• Cell Biology

Background:

• Mantle cell lymphoma (MCL) often relapses after initial treatment, indicating the presence of drug-resistant, clonogenic cells.
• Aldehyde dehydrogenase (ALDH) is an intracellular enzyme linked to drug resistance and cancer stem cell populations in various malignancies.

Purpose of the Study:

• To investigate the role of ALDH expression in MCL.
• To explore the therapeutic potential of CpG oligonucleotides in targeting ALDH-positive MCL cells.

Main Methods:

• Studied ALDH expression in MCL patient samples.
• Utilized synthetic CpG oligonucleotide 2006 (CpG) to treat MCL cells.
• Assessed the effects of CpG on ALDH(+) MCL cell frequency, differentiation, and tumor formation in vitro and in vivo.
• Investigated the synergy between CpG and bortezomib.

Main Results:

• Identified small populations of ALDH-positive (ALDH(+)) MCL cells that were highly clonogenic, quiescent, and drug-resistant.
• CpG treatment reduced quiescent ALDH(+) MCL cells, induced plasma cell differentiation, and limited tumor formation.
• CpG enhanced the efficacy of bortezomib, correlating with the induction of the unfolded protein response.

Conclusions:

• CpG oligonucleotides may represent a novel therapeutic strategy to target resistant ALDH(+) MCL stem cells.
• CpG can improve the activity of proteasome inhibitors like bortezomib in MCL treatment.